
Episode 11: Nephmadness Special! Matt Sparks and Aarushi Varshney on C3G
Episode 11
In this episode, hosts Dr. Kenar Jhaveri and Dr. Koyal Jain are joined by Dr. Matt Sparks (co-creator of NephMadness) and Dr. Aarushi Varshney to discuss the evolving landscape of C3 Glomerulopathy (C3G). The conversation highlights the shift from traditional electron microscopy-based classifications to modern immunofluorescence-based diagnosis, as well as the groundbreaking arrival of two new FDA-approved targeted therapies. The NephMadness Matchup This episode focuses on the C3G bracket pitting two critical aspects of C3G against each other: Team Diagnosis: Focusing on the challenges of distinguishing C3G from infection-related GN or monoclonal gammopathy. Team Treatment: Highlighting the new era of factor B and C3 inhibitors that are revolutionizing patient outcomes. Key Takeaways 1. Challenges in Diagnosis The "Two Orders of Magnitude" Rule: Modern diagnosis is based on immunofluorescence (IF) showing C3 deposition that is at least two orders of magnitude greater than any other immunoglobulin. C3G vs. PIGN: It can be difficult to distinguish C3G from Post-Infectious Glomerulonephritis (PIGN). Clinical clues include patient age, the persistence of low C3 levels after infection resolution, and the presence (or absence) of sub-epithelial humps on pathology. The Role of Monoclonal Gammopathy: In older patients, it is critical to rule out monoclonal gammopathy (using SPEP and free light chain assays) as a driver of complement activation. 2.
Publisher
GN in Ten
Link
share.transistor.fm/s/72477cca
Published
March 11, 2026
Duration
23 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Host
International Society of Glomerular Disease
GN in Ten
@gninten
#nephmadness #mattsparks #aarushivarshney #medicine #lifesciences
